MAZE - Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc. Common Stock Logo

MAZE - Maze Therapeutics, Inc. Common Stock

https://www.mazetx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Celsius Holdings ( NASDAQ:CELH ) , Coincheck Group ( NASDAQ:CNCK )
Benzinga • 1 month, 3 weeks ago • score: 0.14
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Alex Markgraff initiated coverage on Coincheck Group N.V.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.

52W High
$19.19
52W Low
$6.71
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2024-09-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
6.71
EV/Revenue (<3 favorable)
2.72
P/S (TTM) (<3 favorable)
3.14
P/B (<3 favorable)
N/A
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
11.49%
Institutions (25–75% balanced)
56.82%
Shares Outstanding
43,777,000
Float
9,631,100
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
As of 2024-09-30 (Overview)
Revenue (TTM)
167,500,000
Gross Profit (TTM)
167,500,000
EPS (TTM)
-0.42
Profit Margin (>10% good)
0.33%
Operating Margin (TTM) (higher better)
-9.69%
ROE (TTM) (>15% strong)
N/A
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.3405
Previous
0.2045
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025